Program for Experimental and Theoretical Modeling (PETM)

 ABOUT | PEOPLE | PROJECTS | PUBLICATIONS | NEWS | SEMINARS
 RESEARCH OPPORTUNITIES  | MEETINGS | COLLABORATIONS

---

          Liver Meeting (AASLD), Washington, DC, USA, Oct 20-24, 2017

Estimating the contamination level that caused an outbreak of acute hepatitis C (AHC) transmitted by IV injection of contrast material during computerized tomography (CT). Eyal Shteyer, Louis Shekhtman, Inna Gafanovich, Dana Wolf, Hefziba Ivgi, Rima Barsuk, Daniela armoni, Michal Cohen Eliav, Skorochod Yizhak, Breuer Gavriel, Ran Tur-kaspa, Yonit Weil Wiener, Marian Major, Adi Stern, Sherry Peretz-Harari, ScottJ. Cotler,  Tal Zinger and Harel Dahari, Yoav Lurie

Modeling hepatitis delta virus dynamics during ritonavir boosted lonafarnib treatment–the LOWR HDV-3 study. Preeti Dubey, Christopher Koh, Pallavi Surana, Susan L. Uprichard,  Ma Ai Thanda Han, Nancy Fryzek, Devika Kapuria, Ohad Etzion, Varun Takyar, Yaron Rotman, Cihan Yurdaydin, Jeffrey S. Glenn, Scott J. Cotler, Theo Heller and Harel Dahari

Modeling in humanized mice and patients suggests that antihistamine chlorcyclizine HCl not only blocks HCV infection/entry but also viral. Preeti Dubey, Christopher Koh, Nathaniel Borochov, Susan L. Uprichard, Scott J Cotler, Shanshan He, Michio Imamura, Juan J. Marugan, Kazuaki Chayama, T. Jake Liang, Harel Dahari

Repurposing of the antihistamine chlorcyclizine for chronic hepatitis C infection: A randomized, proof-of-concept, clinical trial. 

 15TH INTERNATIONAL CONFERENCE OF NUMERICAL ANALYSIS AND APPLIED MATHEMATICS,25-30 September 2017, Thessaloniki, Greece

 

HCVMultiscaleDyn: A Simulator For The Multiscale Model Of Hepatitis C Virus Dynamics. Alexander Churkin, Vladimir Reinharz, Harel Dahari and Danny Barash

24th International Symposium on Hepatitis C Virus and Related Viruses, Hyannis, Massachusetts, USA, September 25th-28th 2017

 

A Stochastic Agent-Based Simulation for the Cell-to-Cell Spread of Hepatitis C Viral Infection. Evan Cudone, Karina Durso-Cain, Atesmachew Hailegiorgis, Frederik Graw, Susan L. Uprichard, Harel Dahari

Modeling in humanized mice and patients suggests that antihistamine chlorcyclizine HCl not only blocks HCV infection/entry but also viral production. Preeti Dubey, Christopher Koh, Nathaniel Borochov, Susan L. Uprichard, Scott J Cotler, Shanshan He, Michio Imamura, Juan J. Marugan, Kazuaki Chayama, T. Jake Liang, Harel Dahari

Modeling reveals how vaccination could significantly reduce hepatitis C transmission via syringe sharing. Marian Major¹, Alexander Gutfraind , Qingwen Cui, Louis Shekhtman, Alla Kachko, Scott J Cotler, Behzad Hajarizadeh, Rachel Sacks-Davis, Kimberly Page, Basmattee Boodram, and Harel Dahari

 

INTERNATIONAL HBV MEETING, Washington DC, USA Sept 3 - Sept 6, 2017

 

Modeling serum HBV DNA and HBsAg kinetics during nucleic acid polymer REP2139 monotherapy in HBeAg+ chronically infected HBV patients. Louis Shekhtman, Nathaniel Borochov, Scott J. Cotler, Susan L. Uprichard, Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant, Harel Dahari

Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics. Yuji Ishida, Tje Lin Chung, Michio Imamura, Suranjana Sen, Nobuhiko Hiraga, Hiroshi Yokomichi, Chise Tateno, Laetitia Canini, Alan S. Perelson, Susan L. Uprichard, Harel Dahari , Kazuaki Chayama

Exploring the multiphasic viral kinetics of acute hepatitis B virus infection in humanized chimeric mice using an agent-based modeling approach. Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi, Chise Tateno, Susan L. Uprichard, Kazuaki Chayama, Harel Dahari

 

Society for Mathematical Biology (SMB) Annual meeting, University of Utah campus, Salt Lake City July 17-20, 2017

Mathematical modeling of hepatitis C virus (HCV) kinetics during antihistamine chlorcyclizine HCl based treatment. Preeti Dubey, Christopher Koh, Nathaniel Borochov, Shanshan He, Michio Imamura, Juan J. Marugan, Kazuaki Chayama, T. Jake Liang, Harel Dahari

An agent-based modeling of hepatitis B virus kinetics in humanized chimeric mice. Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi , Chise Tateno,Susan L. Uprichard, Kazuaki Chayama,Harel Dahari

An Efficient and Reliable Method for the Numerical Solution of PDE Multiscale Model with Age of Hepatitis C Virus Dynamics during Drug Treatment. Vladimir Reinharz, Harel Dahari ,Danny Barash

 

Viral Dynamics: Past, Present, & Future Eldorado Hotel and Spa, Santa Fe, NM  May 5-7, 2017

 

Infection in space – accounting for target cell tropism when analyzing viral spread. Peter Kumberger, Paola Carrillo-Bustamante, Karina Durso, Andrea Imle, Nikolas Schnellbächer, Thomas Wollmann, Harel Dahari, Ulrich Schwarz, Karl Rohr, Oliver T. Fackler, Susan Uprichard, Frederik Graw

Multiscale Modeling of HCV infection in vitro reveals insights into the dynamics HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir. Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S. Perelson, and Susan L. Uprichard

A Stochastic Agent-Based Simulation for the Cell-to-Cell Spread of Hepatitis C Viral Infection. Evan Cudone, Karina Durso-Cain, Atesmachew Hailegiorgis, Frederik Graw, Susan L. Uprichard, Harel Dahari

 

Agent-Based Modeling (ABM) 17: A Symposium That Advances the Science of ABM,San Diego, CA, April 20-22, 2017

 

An agent-based modeling of hepatitis B virus kinetics in humanized chimeric mice. Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi , Chise Tateno,Susan L. Uprichard, Kazuaki Chayama,Harel Dahari

52^nd Annual Meeting of The International Liver Congress (EASL) Amsterdam, The Netherlands, April 19-23, 2017

Nucleic acid polymer REP2139 monotherapy reveals a short half-life of serum HBsAg in HBeAg+ chronically infected HBV patients. Nathaniel Borochov, Scott J. Cotler, Susan L. Uprichard, Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant, Harel Dahari

Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago. Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram, Scott J Cotler, Marian Major, Harel Dahari

A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study. Christopher Koh, Pallavi Surana, Ma Ai Thanda Han, Nancy Fryzek, Devika Kapuria, Ohad Etzion, Varun Takyar, Yaron Rotman, Raissa Canales, Harel Dahari, Cihan Yurdaydin, Jeffrey S. Glenn and Theo Heller

Characterization of HDV and HBV kinetics during acute co-infection and interferon-alpha treatment in uPA/SCID chimeric mice with humanized livers. Takuro Uchida,Kevin Walsh, Nobuhiko Hiraga, Michio Imamura, Christopher Koh, Jeffrey Glenn, Susan L. Uprichard, Theo Heller, Harel Dahari, Kazuaki Chayama. Boston, MA, USA, Nov 9-13, 2016 (Oral talk).Journal Hepatology 2016; 64:1(Suppl): 9-10A

Characterization of HEV kinetics during ribavirin monotherapy post transplantation. Sebastien Lhomme, Swati DebRoy, Florence Abravanel, Jacques Izopet, Scott J Cotler, Nassim Kamar, Harel Dahari.   Boston, MA, USA, Nov 9-13, 2016 (Oral talk). Journal Hepatology 2016; 64:1(Suppl): 134A

Silibinin treatment for hepatitis D: in vitro and in vivo. Emma Reungoat, Dulce Alfaiate, Inna Gafanovich, Ilana Dery, Orna Mor, Ralf Pohl, Nesma Bensalah, Chloé Montès, Camille Sureau, Scott J Cotler , Harel Dahari, Fabien Zoulim, Yoav Lurie, Eve-Isabelle Pécheur. Boston, MA, USA, Nov 9-13, 2016. Journal Hepatology 2016; 64:1(Suppl): 928A

 

10^th European Conference on Mathematical & Theoretical Biology and Society for Mathematical Biology Annual Meeting, Nottingham, UK, July 11-15, 2016

Quantifying the extent of cell-to-cell transmission for the spread of hepatitis C virus. Peter Kumberger, Karina Durso, Harel Dahari, Susan Uprichard, Frederik Graw.(Oral presentation). 

Individualized antiviral treatment duration for cure via modelling of early hepatitis C virus kinetics. Harel Dahari, et al.(Oral presentation). 

 

 

51^st Annual Meeting of The International Liver Congress (EASL) Barcelona, Spain, April 13-17, 2016 

 

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.  Laetitia Canini, Christopher Koh, Scott J. Cotler, Susan L. Uprichard, Mark A. Winters, Ma Ai Thanda Han, David E. Kleiner, Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller, Harel Dahari. Journal Hepatology: 2016; ; 64(Suppl no 2): S589

Modeling early HCV kinetics to individualize DAA treatment duration in patients with advanced cirrhosis. Martina Gambato, Laetitia Canini, Sabela Lens, Frederik Graw, María Carlota Londoño, Susan L Uprichard, Zoe Mariño, Enrique Reverter, Conceptio Bartres, Patricia González, Scott J Cotler, Xavier Forns, Harel Dahari.(Oral Presentation). Journal Hepatology: 2016; 64(Suppl no 2): S795.

Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of HBV replication. C Yurdaydin, N Borochov, C Kalkan, S DebRoy, F Karakaya, C Koh, E Karatayli, V Haynes-Williams, SC Karatayli, L Canini, SL Uprichard, AM Bozdayi, I Choong, D Cory, T Heller, SJ Cotler, R Idilman, JS Glenn, H Dahari. (Oral Presentation)  Journal Hepatology, 2016; 64(Suppl no 2): S587.

 

HEP DART 2015: Frontiers in Drug Development for Viral Hepatitis, Maui, Hawaii, USA Dec 6-10, 2015

Individualized DAA treatment duration for cure in patients with cirrhosis via modelling of early HCV kinetics. Martina Gambato, Laetitia Canini, Sabela Lens, Frederik Graw, María Carlota Londoño, Susan L Uprichard, Zoe Mariño, Enrique Reverter, Conceptio Bartres, Patricia González, Scott J Cotler, Xavier Forns, Harel Dahari. Global Antiviral Journal, Volume 11, Suppl. 3

 

10^th Brazilian AIDS Conference and 3rd Brazilian Viral Hepatitis Conference, João Pessoa, Paraiba, Brazil

 

Is viral kinetics useful in the DAA era? Harel Dahari (oral talk)

Where does hepatitis C epidemic is heading in the best and worst scenario. Harel Dahari (oral talk)

 

Epidemics – 5^th International Conference on Infectious Disease Dynamics Epidemics, Clearwater, FL, USA; Dec 1-4, 2015

 

Multiscale modeling of hepatitis B virus kinetics in humanized chimeric mice during treatment with lamivudine and/or pegylated interferon-α-2a.  Laetitia Canini, Yuji Ishida, Tje Lin Chung, Karina M. Durso-Cain, Kazuaki Chayama, Alan S. Perelson, Susan L. Uprichard, Harel Dahari. Challenges issue of Epidemics http://www.sciencedirect.com/science/journal/17554365/10.

 

Modeling the probability of hepatitis C virus transmission in injecting drug users as a function of viral load.  Qingwen Cui, Alexander Gufraind, Basmattee Boodram, Scott J Cotler, Harel Dahari, Marian Major. Hepatology 2015; 62:1(Suppl): 1114A

 

Individualized DAA treatment duration for cure in patients with cirrhosis via modelling of early HCV kinetics.  Martina Gambato, Laetitia Canini, Sabela Lens, Frederik Graw, María Carlota Londoño, Susan L Uprichard, Zoe Mariño, Enrique Reverter, Conceptio Bartres, Patricia González, Scott J Cotler, Xavier Forns, Harel Dahari. Hepatology 2015; 62:1(Suppl): 691A

 

HCV Kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.  Harel Dahari, Laetitia Canini, Frederik Graw, Susan L. Uprichard, Evaldo S.A. Arau´jo, Guillaume Penaranda, Emilie Coquet, Aurelie Riso, Christophe Renou, Marc Bourliere, Scott J. Cotler, Philippe Halfon. (Oral presentation).

 

Modeling the probability of hepatitis C virus transmission as a function of viral load. Qingwen Cui, Alexander Gufraind, Basmattee Boodram, Scott J Cotler, Harel Dahari, Marian Major.

 

Prevalence of End of Treatment RNA-Positivity/Sustained Viral Response in HCV Patients Treated with Sofosbuvir Combination Therapies.  Miguel Malespin, Susan L. Uprichard, Alan S. Perelson, Harel Dahari, Scott J. Cotler.  Prevalence of End of Treatment RNA-Positivity/Sustained Viral Response in HCV Patients Treated with Sofosbuvir Combination Therapies. (Oral presentation).

 

 

Understanding hepatitis delta virus and HBsAg kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. Laetitia Canini, Christopher Koh, Scott J. Xiongce Zhao, Susan L. Uprichard, Vanessa Haynes-Williams, Mark A. Winters, Gitanjali Subramanya, Stewart Cooper, Peter Pinto, Erin Wolff, Rachel Bishop, Ma Ai Thanda Han, David E. Kleiner, Onur Keskin, Ramazan Idilman, Cihan Yurdaydin, Jeffrey S. Glenn, Theo Heller and Harel Dahari.J Hepatol 2015; 62 (Suppl 2): S281-282 (Late Breaker ePoster 36); DOI: 10.1016/S0168-8278(15)30190-2.

 

Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of-Concept Study. Christopher Koh, Laetitia Canini, Harel Dahari, David Cory, Mark A. Winters, Matthew Bys, Ingrid Choong, Jeffrey S. Glenn, Theo Heller.

 

65^th Annual Meeting of the American Association for the study of Liver Diseases. Boston MS, USA: Nov 7 –11, 2014

Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib. Laetitia Canini, Christopher Koh, Scott J. Cotler, David Cory, Mark A. Winters, Matthew Bys, Ingrid Choong, Jeffrey S. Glenn, Theo Heller and Harel Dahari. Hepatology 2014; 60:4(Suppl): 317A (oral presentation).

Prenylation Inhibition with Lonafarnib decreases hepatitis D levels in humans. Christopher Koh, Cihan Yurdaydin, David Cory, Harel Dahari, Vanessa Haynes-Williams, Mark A. Winters, Matthew Bys, Ingrid Choong, Laetitia Canini, Peter Pinto, Erin F. Wolff, Rachel J. Bishop, Stewart Cooper, David E Kleiner, T. Jake Liang, Jay H. Hoofnagle, Jeffrey S. Glenn and Theo Heller. Hepatology 2014; 60:4 (Suppl): 1092A-1093A.

HBV infection in humanized chimeric mice has multiphasic viral kinetics from inoculation to steady state and an HBV half-life of 1 hr. Yuji Ishida, Tje Lin Chung, Michio Imamura, Nobuhiko Hiraga, Laetitia Canini, Susan Uprichard, Alan S. Perelson, Chise Tateno, Harel Dahari, Kazuaki Chayama. Hepatology 2014; 60:4(Suppl): 1023A-1024A.

Modeling HCVcc infection reveals new insights into the dynamics that maintain the in vitro HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir. Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S. Perelson, and Susan L. Hepatology 2014; 60:4 (Suppl): 1165A.

HCV kinetics in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. Swati DebRoy, Nobuhiko Hiraga, Michio Imamura, Laetitia Canini, Ralf T. Pohl, Stefano Persiani, Susan Uprichard, Alan S. Perelson, Chise Tateno, Kazuaki Chayama, Harel Dahari. Hepatology 2014; 60:4(Suppl): 1171A-1172A.

Modeling treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago. Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram, Marian Major, Scott J Cotler, Harel Dahari. Hepatology 2014; 60:4(Suppl): 671A-672A.

 

11^th JSH Single Topic Conference, Hiroshima, Japan, Nov 20-21, 2014

 

Recent Progress in HBV Research: Opening new doors to clinical advance. Susan L Uprichard (oral talk)

 

HBV infection kinetics using human hepatocyte chimeric mouse. Harel Dahari (oral talk)

 

21^st International Symposium on HCV and related Viruses. Banff, Canada, Sep 7-11, 2014

 

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. Harel Dahari, Shimon Shteingart, Inna Gafanovich, Scott J. Cotler, Massimo D’Amato, Ralf T. Pohl, Gali Weiss, Yaakov J. Ashkenazi, Thomas Tichler, Eran Goldin, Yoav Lurie.

Modeling HCVcc infection reveals new insights into the dynamics that maintain in vitro HCV steady state and the mechanisms of action of the NS5A inhibitor daclatasvir. Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S. Perelson, and Susan L. Uprichard.

 

2^nd monothematic workshop on the antiviral mechanism of silibinin during HCV infection, Cologne, Germany, May 2014

 

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Canini L, DebRoy S, Mariño Z, Crespo G, Navasa M, D’Amato M, Ferenci P, Cotler SJ,  Forns X, Perelson AS, Dahari H. (Oral presentation)

 

Israel Association for the Study of the Liver, Eilat, Israel, June 2014

 

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics. Harel Dahari, Shimon Shteingart, Inna Gafanovich, Scott J. Cotler, Massimo D’Amato, Ralf T. Pohl, Gali Weiss, Yaakov J. Ashkenazi, Thomas Tichler, Eran Goldin, Yoav Lurie. (Oral presentation)

 

64^th Annual Meeting of the American Association for the study of Liver Diseases. Washington DC,  Nov 1 –5, 2013

 

Hepatitis C virus kinetic comparison between compensated liver disease patients and patients awaiting liver transplantation treated with intravenous silibinin monotherapy. Canini L, DebRoy S, Mariño Z, Crespo G, Navasa M, D’Amato M, Ferenci P, Cotler SJ,  Forns X, Perelson AS, Dahari H. Hepatology 2013;(Suppl)58 volume 4:758A .

Multiscale mathematical modeling of HBV kinetics in humanized chimeric mice during treatment with lamivudine and/or pegylated interferon-α-2a. Chung TL, Ishida Y, Chayama K, Imamura M, Hiraga N, Uprichard SL, Perelson AS, Dahari H. Hepatology 2013;(Suppl)58 volume 4:655A.

Understanding early hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Guedj J, Rotman Y, Cotler SJ, Schmid P, Albrecht J, Haynes-Williams V, Liang T.J, Hoofnagle J.H, Heller T, Dahari H. Hepatology 2013;(Suppl)58 volume 4:688A .

 

10^th International Conference on Health Policy Statistics; Chicago, IL, USA, Oct 9-11, 2013

 

Integrating rich survey datasets in computational simulations of hepatitis C virus infection among injecting drug users in Chicago area. Alexander Gutfraind, Basmattee Boodram,  Lawrence J. Ouellet, Nikhil Prachand, Stephen Feinstone, Susan M Mniszewski, Richard Novak,  Alan S. Perelson, Sara del Valle, Harel Dahari, Marian Major.

 

20^th International Symposium on HCV and related Viruses. Melbourne, Australia  Oct 7-10, 2013

 

Detailed viral kinetics during liver transplantation (LT) indicates that the liver plays a role in HCV clearance. 20th International Symposium on HCV and related Viruses. Tje Lin Chung, Gonzalo Crespo,Laura Mensa, Sofia Perez-del-Pulgar, Miquel Navasa, Alan S. Perelson, Scott J Cotler, Susan L. Uprichard, Xavier Forns, Harel Dahari. (Oral presentation)

Quantification of HCV cell-to-cell spread using a stochastic modeling approach. Frederik Graw, Danyelle N. Martin, Alan S. Perelson, Susan L. Uprichard, Harel Dahari.

Characterization of intracellular and extracellular of HCV inhibition kinetics during in vitro treatment with DAAs. Natasha Sansone, Harel Dahari, Gitanjali Subramanya, Alan S. Perelson, Susan L. Uprichard.

 

48^th Annual Meeting of the European Association for the Study of the Liver, April 24 - 28, 2013; Amsterdam, the Netherlands

 

HCV kinetics during and after the anhepatic phase: Is the liver the primary site for HCV clearance? Tje Lin Chung, Gonzalo Crespo,Laura Mensa, Sofia Perez-del-Pulgar, Miquel Navasa, Scott J Cotler, Xavier Forns, Harel Dahari. J Hepatol 2013;58(Suppl 1): S229-230.

Modeling HCV kinetics during intravenous silibinin monotherapy in peri-transplant period. Swati DebRoy, Zoe Mariño, Gonzalo Crespo, Miquel Navasa,Massimo D’Amato, Scott J Cotler,  Xavier Forns, Harel Dahari . J Hepatol 2013;58(Suppl 1): S330-331.

 

63^rd Annual Meeting of the American Association for the study of Liver Diseases. San Francisco, CA:  Nov 9 –13, 2012

 

Impact of double filtration plasmapheresis in combination with PEG-IFN and ribavirin in previous non responders: a longitudinal HCV kinetic analysis. Harel Dahari, Maria Rendina, Alfonso Ramunni, Scott J. Cotler, Alan S. Perelson ,Nicola M Castellaneta, Antonino Castellaneta, Marianna Zappimbulso, Roberto Bringiotti, Salvatore F Rizzi, Annamaria Squicciarino, Antonio Francavilla and Alfredo Di Leo. Hepatology 2012;(Suppl)56 volume 4:718.

 

19^th International Symposium on HCV and related Viruses. Venice, Italy, Oct 5-9, 2012

 

Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo. Harel Dahari*, Jeremie Guedj*, Libin Rong*, Patrick Smith, Alan S. Perelson.